MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.
作者:
主题词
老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤药(Antineoplastic Agents);曲线下面积(Area Under Curve);癌, 肾细胞(Carcinoma, Renal Cell);无病生存(Disease-Free Survival);女(雌)性(Female);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);人类(Humans);吲哚类(Indoles);肾肿瘤(Kidney Neoplasms);Logistic模型(Logistic Models);男(雄)性(Male);微RNAs(MicroRNAs);中年人(Middle Aged);寡核苷酸序列分析(Oligonucleotide Array Sequence Analysis);试验预期值(Predictive Value of Tests);前瞻性研究(Prospective Studies);吡咯类(Pyrroles);ROC曲线(ROC Curve);统计学, 非参数(Statistics, Nonparametric);存活率分析(Survival Analysis);治疗结果(Treatment Outcome)
DOI
10.1593/neo.12734
PMID
23308047
发布时间
2021-10-21
- 浏览38

Neoplasia (New York, N.Y.)
1144-52页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文